Penserra Capital Management LLC Fate Therapeutics Inc Transaction History

Penserra Capital Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 15, 2022	SELL	$47.84 - $64.34 $104,291 - $140,261	-2,180 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$59.27 - $95.73 $2,370 - $3,829	40 Added 1.87%	2,180 $129,000
Q2 2021 Aug 12, 2021	BUY	$67.25 - $92.52 $1,345 - $1,850	20 Added 0.94%	2,140 $185,000
Q1 2021 May 13, 2021	BUY	$72.16 - $117.4 $7,937 - $12,914	110 Added 5.47%	2,120 $174,000
Q4 2020 Feb 12, 2021	BUY	$38.09 - $100.95 $48,374 - $128,206	1,270 Added 171.62%	2,010 $182,000
Q3 2020 Nov 13, 2020	BUY	$30.41 - $40.5 $22,503 - $29,970	740 New	740 $29,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $222M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Penserra Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Penserra Capital Management LLC with notifications on news.